Aceves-Franco Luis Abraham, Sanchez-Aguilar Oscar Eduardo, Barragan-Arias Allen Rafael, Ponce-Gallegos Marco Antonio, Navarro-Partida Jose, Santos Arturo
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64849, Nuevo Leon, Mexico.
Centro de Retina Medica y Quirurgica, S.C., Centro Medico Puerta de Hierro, Zapopan 45116, Jalisco, Mexico.
Biomedicines. 2023 Jul 5;11(7):1901. doi: 10.3390/biomedicines11071901.
Ophthalmic drug delivery to the posterior segment of the eye has been challenging due to the complex ocular anatomy. Intravitreal injection of drugs was introduced to deliver therapeutic doses in the posterior segment. Different posterior segment diseases including age-related macular degeneration, diabetic macular edema, retinal vein occlusions, uveitis, and cystoid macular edema, among others, have been historically treated with intravitreal corticosteroids injections, and more recently with intravitreal corticosteroids drug implants. Triamcinolone acetonide (TA) is the most frequently used intraocular synthetic corticosteroid. Using nanoparticle-based TA delivery systems has been proposed as an alternative to intravitreal injections in the treatment of posterior segment diseases. From these novel delivery systems, topical liposomes have been the most promising strategy. This review is oriented to exhibit triamcinolone acetonide drug evolution and its results in treating posterior segment diseases using diverse delivery platforms.
由于眼部解剖结构复杂，向眼后段递送眼科药物一直具有挑战性。玻璃体内注射药物被引入以在眼后段递送治疗剂量。包括年龄相关性黄斑变性、糖尿病性黄斑水肿、视网膜静脉阻塞、葡萄膜炎和黄斑囊样水肿等在内的不同眼后段疾病，历史上一直通过玻璃体内注射皮质类固醇进行治疗，最近则采用玻璃体内皮质类固醇药物植入物进行治疗。曲安奈德（TA）是最常用的眼内合成皮质类固醇。基于纳米颗粒的TA递送系统已被提议作为治疗眼后段疾病时玻璃体内注射之外的一种选择。在这些新型递送系统中，局部脂质体是最有前景的策略。本综述旨在展示曲安奈德药物的发展历程及其使用不同递送平台治疗眼后段疾病的结果。
